{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":19,"n_cols":5,"rows_kept":19,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[12,2,12,3],[13,2,13,3],[15,2,15,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910830159803321"]
[null,null,"Titolo",null,"Blood and marrow transplantation long term management : survivorship after transplant / / edited by Bipin N Savani, Andre Tichelli"]
[null,null,"Pubbl/distr/stampa",null,"Hoboken, New Jersey : , : Wiley-Blackwell, , [2021]"]
[{"$nulls":4},"2021"]
[null,null,"ISBN",null,"1-119-61273-X"]
[{"$nulls":4},"1-119-61278-0"]
[{"$nulls":4},"1-119-61274-8"]
[null,null,"Edizione",null,"[Second edition.]"]
[null,null,"Descrizione fisica",null,"1 online resource (467 pages)"]
[null,null,"Disciplina",null,"617.44"]
[null,null,"Soggetti",null,"Bone marrow - Transplantation"]
[{"$nulls":4},"Hematopoietic stem cells - Transplantation"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"List of contributors -- Section 1 Late effects concepts -- 1 Introduction -- Bipin N Savani and Andre Tichelli -- 2 International Blood and Marrow registries trends on long-term data collection -- Rachel Phelan, Jakob Passweg, Helen Baldomero, Minako Iida, Yoshiko Atsuta, Shinichiro Okamoto, Mahmoud Aljurf, Feras Alfraih, and Bronwen Shaw -- 3 Long-term transplant clinic setup -- André Tichelli, Bipin Savani, Shahrukh K Hashmi, Navneet S Majhail, and Alicia Rovó -- 4 Telemedicine in patient care of long-term survivors -- Catherine Lee, Mihkaila Wickline, and Mary Flowers -- 5 Long-term follow-up calendar -- André Tichelli, Bipin N Savani, Shahrukh K Hashmi, Navneet S Majhail, and Alicia Rovó -- 6 Late effects after allogeneic hematopoietic stem cell transplantation -- Shahrukh Hashmi and Yoshihiro Inamoto -- 7 Late effects after autologous hematopoietic stem cell transplantation -- Rajshekhar Chakraborty and Betty Hamilton -- 8 Long-term follow-up of children -- Paul Carpenter -- 9 Graft-versus-host disease and GvHD-associated late effects -- David Michonneau, Aurélien Sutra-del-Galy, and Gérard Socié -- 10 Screening and prevention guidelines for hematopoietic cell transplant survivors -- Neel S Batt, J Douglas Rizzo, and Navneet S Majhail -- 11 Biology of survivorship after BMT -- Smita Bhatia -- Section 2 Specific late effects -- 12 Secondary malignancies -- Aurélien Sutra-del-Galy, David Michonneau, and Gérard Socié -- 13 Anti-infective prophylaxis, "]
[{"$nulls":4},"immunization and prevention of late infectious complications -- Per Ljungman -- 14 Seasonal virus infections in recipients and exposure to family members -- Nosha Farhadfar, Zeina Al-Mansour, and John Wingard -- 15 Monitoring and management of hepatitis B, C, and HIV infection before and after transplantation -- Enric Carreras and Montserrat Rovira -- 16 Skin chronic graft-versus-host disease -- Attilio Oliveri and Andrea Bacigalupo -- 17 Ocular complications -- Alicia Rovó, André Tichelli, and Yoshihiro Inamoto -- 18 Oral and dental complications -- Hildegard Greinix -- 19 Thyroid late complications -- Juliana Matthews, Leslee Matheny, and Shubhada Jagasia -- 20 Pre-transplant considerations in gender, reproductive, and sexual health -- Dana Shanis, Jeanne Murphy, Kate Debiec, Betty K Hamilton, Shawna Boyle, and Pamela Stratton -- 21 Post-transplant considerations in gender, reproductive, and sexual health -- Jeanne Murphy, Dana Shanis, Kate Debiec, Betty K Hamilton, Shawna Boyle, and Pamela Stratton -- 22 Fertility issues, fertility preservation, and pregnancy outcome in long-term survivors -- Alicia Rovó, Alison W Loren, André Tichelli, and Nina Salooja -- 23 Sexual dysfunction in long-term survivors -- Rebecca Hunter, Sarah Thilges, Janna Gordon, Kristy Luke, Karla Cavazos, Emilee Moeke, Colleen Bruen, and Sunita Natha -- 24 Non-infectious pulmonary late complications -- Ayman O Soubani -- 25 Cardiac and arterial complications -- Alicia Rovó and André Tichelli -- 26 Cardiovascular risk factors -- Kimberley Doucette and Minoo Battiwalla -- 27 Gastrointestinal complications -- Sumona Bhattacharya, Steven Pavletic and Theo Heller -- 28 Hepatic complications -- Christy Ann L Gilman Christopher Koh, Steven Pavletic, and Theo Heller -- 29 Renal complications -- Insara Jaffer Sathick, and Sangeeta Hingorani -- 30 Post-Transplantation Bone Disease -- Christine Ducan -- 31 Neurological late complications -- Enrico Maffini -- 32 Neurogognitive dysfunction -- David Buchbinder -- 33 Psychological distress -- Anna Barata, Aasha I Hoogland and Heather SL Jim -- 34 Persistent chronic fatigue -- Sandy Mitchell -- 35 Social issues -- Sanghee Hong and Navneet Majhail -- 36 Health-related quality of life in adult and pediatric survivors -- Lori Wiener, Jenny Hoag, and Tamryn Gray -- Section 3 Supportive care and patients reported outcome -- 37 Immunosuppressive agents and monitoring in long-term survivors -- Katie Culos and Katie Gatwood -- 38 Nutritional support and nutritional supplementation -- Shigeo Fuji -- 39 Daily routines and healthy lifestyle guidelines -- Melissa Logue -- 40 Prevalent psychosocial adjustment issues and solutions: lifestyle and social challenges -- Katrina Stokes -- 41 Complementary and alternative medicine in HSCT -- Ibrahim N Muhsen, Bipin N Savani, and Shahrukh Hashmi -- 42 Impact of adherence in outcome of long-term survivors -- Corien Eeltink and Annika Kisch -- 43 Prominent role of allied health professionals -- Catherine E Lucid -- 44 Patient reported outcome -- Hélène Schoemans -- 45 Caregivers of long-term survivors -- Angela Moreschi Woods -- 46 Patient's perspective: memory of a recovered lymphomaniac -- Michael Brown -- Appendix 1 Commonly used transplant-related medications in long-term survivors -- Katie Culos and Katie Gatwood -- Appendix 2 The eGVHD App -- Hélène Schoemans -- Index."]
[null,null,null,"Sommario/riassunto","\"Hematopoietic cell transplantation (HCT) provides curative therapy for a variety of diseases. Over the past several decades, significant advances have been made in the field of HCT and now HCT has become an integral part of treatment modality for a variety of hematologic malignancies and some nonmalignant diseases. HCT remains an important treatment option for a wide variety of hematologic and nonhematologic disorders, despite recent advances in the field of "]
[{"$nulls":4},"immunologic therapies. Factors driving this growth include expanded disease indications, greater donor options (expanding unrelated donor registries and haploidentical HCT), and accommodation of older and less fit recipients. The development of less toxic pretransplant conditioning regimens, more effective prophylaxis of graft-versus-host disease (GVHD), improved infection control, and other advances in transplant technology have resulted in a rapidly growing number of transplant recipients surviving long-term free of the disease for which they were transplanted. The changes over decades in the transplant recipient population and in the practice of HCT will have almost inevitably altered the composition of the long-term survivor population over time. Apart from an increasingly older transplant recipient cohort, the pattern of transplant indications has shifted from the 1990s when chronic myeloid leukemia made up a significant proportion of allo-HCT indications. Changes in cell source, donor types, conditioning regimens, GVHD prophylaxis, and supportive care have all occurred, with ongoing reductions in both relapse and non-relapse mortality (NRM) have been demonstrated\"--"]